Prostate-specific antigen screening for prostate cancer has reduced cancer deaths up to 31%, according to a new report.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) Report said personal risk assessment will reduce the number of unnecessary biopsies by 33%.

The ERSPC study ran from 1992 and involved 162,000 men between the ages of 55 and 69, in seven European countries.